ABL1 is altered in 0.81% of plasma cell neoplasm patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains AFF1 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

BCR is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BCR status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains DEK status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ELL status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

FLT3 is altered in 0.81% of plasma cell neoplasm patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2A is altered in 2.51% of plasma cell neoplasm patients [2].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KMT2A status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

MECOM is altered in 0.84% of plasma cell neoplasm patients [2].

MECOM is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains MECOM status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains MLLT1 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains MLLT10 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains MLLT4 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains NRIP3 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains NUP214 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

PBX1 is altered in 0.89% of plasma cell neoplasm patients [2].

PBX1 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains PBX1 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains RPN1 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

TCF3 is altered in 0.83% of plasma cell neoplasm patients [2].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53 is altered in 8.87% of plasma cell neoplasm patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [3].